This study, called RAISE, is testing a new drug called BB-031 for people who have had an acute ischemic stroke. An ischemic stroke happens when a blood clot blocks blood flow to the brain. The study aims to see how safe BB-031 is and how well people tolerate it. You might be able to join if you are 18 or older, have had an acute ischemic stroke affecting the front part of your brain, and your symptoms started within 24 hours. You would receive either BB-031 or a placebo (an inactive substance like salt water). The main goal is to check for serious bleeding in the brain within 24 hours of treatment. The study plans to enroll 228 patients, but its current recruitment status is unclear.

Study design

This is a randomized, placebo-controlled, double-blinded study with two parts, aiming to enroll 228 participants. Participants will receive either BB-031 or a placebo.

What's involved

You would be screened after a stroke diagnosis and then receive a single dose of the study drug or placebo. You would be followed for 90 days after treatment.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 90 days after receiving treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.